{"organizations": [], "uuid": "6c471ef3a93f723bd9f97b733300d7cb76a66f60", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180521.html", "section_title": "Archive News &amp; Video for Monday, 21 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-urogen-pharma-announces-positive-i/brief-urogen-pharma-announces-positive-interim-results-from-pivotal-phase-3-olympus-trial-of-ugn-101-idUSASC0A333", "country": "US", "domain_rank": 408, "title": "BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.006, "site_type": "news", "published": "2018-05-22T03:23:00.000+03:00", "replies_count": 0, "uuid": "6c471ef3a93f723bd9f97b733300d7cb76a66f60"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-urogen-pharma-announces-positive-i/brief-urogen-pharma-announces-positive-interim-results-from-pivotal-phase-3-olympus-trial-of-ugn-101-idUSASC0A333", "ord_in_thread": 0, "title": "BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101", "locations": [], "entities": {"persons": [], "locations": [{"name": "pivota", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "urogen pharma ltd", "sentiment": "negative"}, {"name": "brief-urogen pharma", "sentiment": "negative"}, {"name": "olympus", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) - Urogen Pharma Ltd:\n* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGELâ„¢) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)\n* UROGEN PHARMA LTD - INTERIM RESULTS SHOWED COMPLETE RESPONSE (CR) RATE OF 59 PERCENT IN PATIENTS WITH LOW-GRADE UTUC\n* UROGEN PHARMA LTD - OLYMPUS TRIAL CONTINUES TO ENROLL PATIENTS, AND TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2018\n* UROGEN PHARMA LTD - CRS TO DATE REMAIN DURABLE AT THREE, SIX AND NINE-MONTH FOLLOW-UP IN PHASE 3 OLYMPUS TRIAL OF UGN-101\n* UROGEN PHARMA LTD - UGN-101 APPEARED TO BE WELL-TOLERATED WITH MOST TREATMENT-EMERGENT ADVERSE EVENTS CHARACTERIZED AS MILD OR MODERATE AND TRANSIENT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-22T03:23:00.000+03:00", "crawled": "2018-05-22T19:27:13.012+03:00", "highlightTitle": ""}